Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors
- PMID: 15753651
- DOI: 10.4161/cbt.4.3.1497
Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors
Abstract
Cdk9 is a member of the Cdc2-like family of kinases. Its cyclin partners are members of the family of cyclin T (T1, T2a and T2b) and cyclin K. The Cdk9/Cyclin T complex appears to be involved in regulating several physiological processes. Recently, Cdk9 has been identified as a regulator of the differentiation program of several cell types, such as muscle cells, monocytes and lymphocytes, suggesting that it may have a function in controlling specific differentiative pathways. We analyzed whether Cdk9 and Cyclin T1 may be involved in the regulation of neuron and astrocyte differentiation. Cdk9 and Cyclin T1 expression levels were monitored during the differentiation program of neuroblastoma and astrocytoma cell lines. Our results suggest that Cdk9/Cyclin T1 complex may be required for neuron differentiation induced by retinoic acid, because the expression level of the complex varies during differentiation, but no significant changes were observed in its expression in the astrocytoma cell line. In addition, the expression of Cdk9 and Cyclin T1 was evaluated by immunohistochemistry in samples of neuroblastoma, PNET (Primary Neuroectodermal Tumor) and astrocytoma tumors of different grades, in order to assess whether there was a correlation between Cdk9 expression and tumor grading. Our results show that in neuroblastoma and PNET tumor samples Cdk9 is more expressed the more differentiated the tumor is. Conversely, no significant alteration of Cdk9 expression was observed in astrocytoma tumor samples of different grades, thus confirming the results obtained for the cell lines.
Similar articles
-
CDK9/CYCLIN T1 expression during normal lymphoid differentiation and malignant transformation.J Pathol. 2004 Aug;203(4):946-52. doi: 10.1002/path.1588. J Pathol. 2004. PMID: 15258998
-
The role of the Cdk9/Cyclin T1 complex in T cell differentiation.J Cell Physiol. 2007 Aug;212(2):411-5. doi: 10.1002/jcp.21032. J Cell Physiol. 2007. PMID: 17352406
-
Cdk9/Cyclin T1 complex: a key player during the activation/differentiation process of normal lymphoid B cells.J Cell Physiol. 2008 Apr;215(1):276-82. doi: 10.1002/jcp.21311. J Cell Physiol. 2008. PMID: 18205180
-
CDK9: from basal transcription to cancer and AIDS.Cancer Biol Ther. 2002 Jul-Aug;1(4):342-7. Cancer Biol Ther. 2002. PMID: 12432243 Review.
-
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases.Cell Cycle. 2008 Dec;7(23):3664-8. doi: 10.4161/cc.7.23.7122. Epub 2008 Dec 4. Cell Cycle. 2008. PMID: 19029809 Review.
Cited by
-
Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.ISRN Oncol. 2013 Jun 6;2013:305371. doi: 10.1155/2013/305371. Print 2013. ISRN Oncol. 2013. PMID: 23840966 Free PMC article.
-
Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters.Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17349-54. doi: 10.1073/pnas.0603079103. Epub 2006 Nov 6. Proc Natl Acad Sci U S A. 2006. PMID: 17088550 Free PMC article.
-
The Prognostic Role of CDK9 in Bladder Cancer.Cancers (Basel). 2022 Mar 15;14(6):1492. doi: 10.3390/cancers14061492. Cancers (Basel). 2022. PMID: 35326643 Free PMC article.
-
Potent pro-apoptotic combination therapy is highly effective in a broad range of cancers.Cell Death Differ. 2022 Mar;29(3):492-503. doi: 10.1038/s41418-021-00869-x. Epub 2021 Sep 17. Cell Death Differ. 2022. PMID: 34535764 Free PMC article.
-
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664. Pharmaceutics. 2023. PMID: 36839989 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous